99mTc-labeled therapeutic inhaled amikacin loaded liposomes

Journal of Liposome Research

Volumn 23, Issue 4, 2013, Pages 336-342

  Lee, Jae Ho ^a   Cheng, Kenneth T ^a   Malinin, Vladimir ^b   Li, Zhili ^b   Yao, Zhengsheng ^a   Lee, Sung Jin ^a   Gould, Christine M ^c   Olivier, Kenneth N ^c   Chen, Clara ^a   Perkins, Walter R ^b   Paik, Chang H ^a  

^a Radiopharmaceutical Laboratory   (United States)

^b Insmed Inc   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

99mTc labeled liposome encapsulated amikacin; Radiolabeling; Size exclusion analysis

Indexed keywords

AMIKACIN; ANION EXCHANGE RESIN; ASCORBIC ACID; LIPOSOME; PERTECHNETIC ACID TC 99M; REDUCING AGENT; STANNOUS CHLORIDE; TECHNETIUM 99M;

ANION EXCHANGE; ARTICLE; CONTROLLED STUDY; DRUG PURIFICATION; ENCAPSULATION; GAMMA SCINTIGRAPHY; ISOTOPE LABELING; LIGHT SCATTERING; NEBULIZATION; NEBULIZER; PARTICLE SIZE; PRIORITY JOURNAL; RADIOACTIVITY; SURFACE PROPERTY;

ADMINISTRATION, INHALATION; AMIKACIN; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; LIPOSOMES; ORGANOTECHNETIUM COMPOUNDS; PARTICLE SIZE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84885461287     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2013.819889     Document Type: Article

References (33)

1. Antos M, Trafny EA, Grzybowski J. (1995). Antibacterial activity of liposomal amikacin against Pseudomonas aeruginosa in vitro. Pharmacol Res 32:85-7. (Pubitemid 26003802)
2. Arulsudar N, Subramanian N, Mishra P, et al. (2003). Preparation, characterisation and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine. J Drug Target 11:187-96. (Pubitemid 37236332)
3. Baljosevic I, Subarevic J, Subarevic V, et al. (2002). Surgical tracheotomy in congenital anomalies of the larynx. Srp Arh Celok Lek 130: 37-9.
4. Barker SA, Taylor KMG, Short MD. (1994). The deposition and clearance of liposome-entrapped Tc-99m-DTPA in the human respiratory-tract. Int J Pharmaceutics 102:159-65.
5. Caride VJ. (1990). Technical and biological considerations on the use of radiolabeled liposomes for diagnostic-imaging. Nucl Med Biol 17:35-9. (Pubitemid 20026252)
6. Conway J. (2012). Lung imaging-two dimensional gamma scintigraphy, SPECT, CT and PET. Adv Drug Deliv Rev 64:357-68.
7. Elbayoumi TA, Torchilin VP. (2006). Enhanced accumulation of long-circulating liposomes modified with the nucleosomespecific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging 33: 1196-205. (Pubitemid 44484476)
8. Farr S J, Kellaway IW, Parryjones DR, Woolfrey SG. (1985). Technetium-99m as a marker of liposomal deposition and clearance in the human-lung. Int J Pharmaceutics 26:303-16. (Pubitemid 16228628)
9. Geller DE. (2009). Aerosol antibiotics in cystic fibrosis. Respir Care 54: 658-69.
10. Grabielle-Madelmont C, Lesieur S, Ollivon M. (2003). Characterization of loaded liposomes by size exclusion chromatography. J Biochem Biophys Methods 56:189-217. (Pubitemid 36776602)
11. Koizumi K, Uchiyama G, Arai T, et al. (1992). A new liver functional study using Tc-99m DTPA-galactosyl human serum albumin: evaluation of the validity of several functional parameters. Ann Nucl Med 6:83-7.
12. Lesieur S, Grabielle-Madelmont C, Paternostre MT, Ollivon M. (1991). Size analysis and stability study of lipid vesicles by high-performance gel exclusion chromatography, turbidity, and dynamic light scattering. Anal Biochem 192:334-43.
13. Lesieur S, Grabiellemadelmont C, Paternostre M, Ollivon M. (1993). Study of size distribution and stability of liposomes by high performance gel exclusion chromatography. Chem Phys Lipids 64: 57-82. (Pubitemid 23290866)
14. Liu TW, MacDonald TD, Shi J, et al. (2012). Intrinsically copper-64- labeled organic nanoparticles as radiotracers. Angew Chem Int Ed Engl 51:13128-31.
15. Malam Y, Loizidou M, Seifalian AM. (2009). Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30:592-9.
16. Marier JF, Brazier JL, Lavigne J, Ducharme MP. (2003). Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 52: 247-52. (Pubitemid 36986886)
17. Minic P, Fustic S, Solyom E, et al. (2010). A multi-cycle open label study of nebulized liposomal amikacin (ARIKACETM) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Pediatr Pulmonol 45:(S33).
18. Moss RB. (2002). Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121:55-63. (Pubitemid 34114228)
19. Mugabe C, Azghani AO, Omri A. (2005). Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 55:269-71. (Pubitemid 40331158)
20. Okusanya OO, Bhavnani SM, Hammel J, et al. (2009). Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 53:3847-54.
21. Ollivon M, Walter A, Blumenthal R. (1986). Sizing and separation of liposomes, biological vesicles, and viruses by high-performance liquid chromatography. Anal Biochem 152:262-74. (Pubitemid 16144721)
22. Omri A, Beaulac C, Bouhajib M, et al. (1994). Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 38:1090-5. (Pubitemid 24150843)
23. Patton JS. (1996). Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 19:3-36. (Pubitemid 26167852)
24. Phillips WT. (1999). Delivery of gamma-imaging agents by liposomes. Adv Drug Deliv Rev 37:13-32. (Pubitemid 29164497)
25. Qiu L, Lin JG, Ju XH, et al. (2011). Structural investigation of technetium-diphosphonate complex 99mTc-MDP. Chin J Chem Phys 24:295-304.
26. Richardson VJ, Ryman BE, Jewkes RF, et al. (1979). Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. Br J Cancer 40:35-43. (Pubitemid 9225975)
27. Saari SM, Vidgren MT, Koskinen MO, et al. (1998). Regional lung deposition and clearance of Tc-99m-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 113:1573-9. (Pubitemid 28307162)
28. Saari M, Vidgren MT, Koskinen MO, et al. (1999). Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int J Pharm 181:1-9. (Pubitemid 29199882)
29. Shah SP, Misra A. (2004). Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech 5:e65.
30. Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-60. (Pubitemid 40282557)
31. Vidgren M, Waldrep JC, Arppe J, et al. (1995). A study of Tc-99mlabeled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int J Pharm 115:209-16.
32. Weers J, Metzheiser B, Taylor G, et al. (2009). A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 22:131-8.
33. Weers JG, Bell J, Chan HK, et al. (2010). Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv 23:S5-23.